What is NDC 59651-204?

59651-204 is the product NDC for Capecitabine, Capecitabine 150 mg/1 tablet, listed with the FDA by Aurobindo Pharma Limited. It has 2 package NDCs, shown above in 10- and 11-digit form.

Aurobindo Pharma Limited, NDC labeler code 59651. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Capecitabine?

30 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Capecitabine NDC 59651-204 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-204Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0204Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-204-10	5965102041059651020410	1 BLISTER PACK in 1 CARTON (59651-204-10) / 10 TABLET in 1 BLISTER PACKMarketed from Apr 17, 2018
59651-204-60	5965102046059651020460	60 TABLET in 1 BOTTLE (59651-204-60)Marketed from Apr 17, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Capecitabine
Generic name (nonproprietary): capecitabine
Active ingredients: Capecitabine — 150 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aurobindo Pharma LimitedNDC labeler code 59651
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210604
Marketing start: Apr 17, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Nucleic Acid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 59651-204_eee71cc5-a7d5-4e51-ab02-2fae12418585SPL ID eee71cc5-a7d5-4e51-ab02-2fae12418585SPL set ID 56441153-a1e5-4fdc-96d6-f21baa6b5fbeRxCUI 200327, 200328UNII 6804DJ8Z9U
Pharmacologic class: Nucleoside Metabolic Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651020410 followed by a unit qualifier and the quantity

Package 59651-0204-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 8, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Capecitabine tablets are a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patient…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 59651-204

What is NDC 59651-204?: 59651-204 is the product NDC for Capecitabine, Capecitabine 150 mg/1 tablet, listed with the FDA by Aurobindo Pharma Limited. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Capecitabine.
What is the active ingredient?: Capecitabine.
Who is the labeler?: Aurobindo Pharma Limited, NDC labeler code 59651. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Capecitabine?: 30 other product NDCs are listed under this name. See all Capecitabine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Capecitabine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Capecitabine	Capecitabine 150 mg/1	Tablet, Film coatedOral	CivicaScript LLC	82249-207	82249-0207-60
Capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	CivicaScript LLC	82249-210	82249-0210-12
Capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	BluePoint Laboratories	68001-644	68001-0644-07
Capecitabine	Capecitabine 150 mg/1	Tablet, Film coatedOral	BluePoint Laboratories	68001-643	68001-0643-06
capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	NorthStar RxLLC	72603-303	72603-0303-01
capecitabine	Capecitabine 150 mg/1	Tablet, Film coatedOral	Camber Pharmaceuticals, Inc.	31722-774	31722-0774-60
capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	Camber Pharmaceuticals, Inc.	31722-775	31722-0775-1231722-0775-60
Capecitabine	Capecitabine 500 mg/1	TabletOral	Quallent Pharmaceuticals Health LLC	82009-112	82009-0112-12
Capecitabine	Capecitabine 500 mg/1	Tablet, Film coatedOral	Cipla USA Inc.	69097-948	69097-0948-08
Capecitabine	Capecitabine 150 mg/1	Tablet, Film coatedOral	Cipla USA Inc.	69097-949	69097-0949-03

All 31 Capecitabine NDCs

Other NDCs under ANDA 210604

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210604
Product	Strength	Form · route	Labeler	Product NDC
Capecitabine	Capecitabine 500 mg/1	TabletOral	Aurobindo Pharma Limited	59651-205